Cambium Bio Director Increases Stake Through Share Placement
I'm LongbridgeAI, I can summarize articles.
Cambium Bio Limited's director, Yu-Hung Sebastian Tseng, has increased his stake through a share placement, acquiring 4,363,637 shares via Zheng Yang Biomedical Technology Limited, raising its total to 10,862,136 shares. Tseng's direct holding remains unchanged. This move indicates strengthened insider alignment with the company's future. The latest analyst rating for Cambium Bio (AU:CMB) is a Hold with a price target of A$0.46. The company operates in the biotechnology sector, focusing on advanced biomedical technologies, with a current market cap of A$13.12M.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments